Drug
Remibrutinib
Remibrutinib: highest development phase Phase 3, developed by Novartis. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Remibrutinib NCT07811869 | Phase 3 | Chronic Pruritus of Unknown Origin |
| Remibrutinib NCT07456891 | Phase 3 | Indication of the Parent Protocol |
| Remibrutinib NCT07816328 | Phase 3 | Chronic Spontaneous Urticaria |
| Remibrutinib NCT06868212 | Phase 3 | Chronic Spontaneous Urticaria (CSU) |
| Remibrutinib NCT07700056 | Phase 3 | Chronic Pruritus of Unknown Origin |
| Remibrutinib NCT07768371 | Phase 3 | IgE-Mediated Food Allergy |
| Remibrutinib NCT07665437 | Phase 3 | Hidradenitis Suppurativa |
Latest
No recent events.
Follow Remibrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.